DOJ and HHS announced on October 22 a six-month pilot program inviting healthcare companies to voluntarily self-disclose potential False Claims Act violations. The program is aimed at strengthening anti-fraud enforcement while creating a structured pathway for providers and companies to report misconduct. As a federal enforcement initiative involving major health agencies, it is a notable healthcare politics development with implications for compliance, oversight, and administration priorities.
